A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

This is a 4 arm (all active) study to determine the safety and efficacy of Alefacept in de
novo kidney transplant recipients.

Inclusion Criteria:

- Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of
transplant procedure

- Subject is a recipient of a de novo kidney transplant

- Subject is a recipient of a kidney from a non-human leukocyte antigen (HLA) identical
related living donor, a non-related living donor, or a deceased donor

Exclusion Criteria:

- Subject has a screening (pre-operative)estimated cluster of differentiation (CD) 4+
T-cell count of < 250 cells/µL

- Subject will receive a kidney with an anticipated cold ischemia time (CIT) of > 30
hours

- Recipient has a positive T or B-cell cross match by investigational site's standard
method of determination

- Subject will receive a kidney from a 50-65 year old deceased donor with one of the
following:

- History of hypertension and a terminal serum creatinine > 1.5 mg/dL

- Cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5
mg/dL

- History of hypertension and cerebrovascular accident as cause of death and a
terminal serum creatinine > 1.5 mg/dL